IP Library Granted Patent US 9,974,910
Granted Patent B2
US 9,974,910 · App. 15/281,176 · Granted May 22, 2018

Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,974,910
App. No.
15/281,176
Granted
May 22, 2018
Kind
B2
Abstract

Described are systems and methods for compensating long term sensitivity drift of catalytic type electrochemical gas sensors used in systems for delivering therapeutic nitric oxide (NO) gas to a patient by compensating for drift that may be specific to the sensors atypical use in systems for delivering therapeutic nitric oxide gas to a patient. The long term sensitivity drift of catalytic type electrochemical gas sensors may be addressed using calibration schedules, which can factor in the absolute change in set dose of NO being delivered to the patient that can drive one or more baseline calibrations. The calibration schedules can be used to reduce the amount of times the sensor goes offline.

Claims (44)

1. A method for compensating nitric oxide sensor drift affiliated with nitric oxide delivery, comprising:

storing, in a non-transitory computer-readable memory affiliated with a nitric oxide delivery system, a calibration line correlating expected output values from a nitric oxide sensor to nitric oxide concentrations and a calibration schedule providing times for performing a plurality of baseline calibrations, the baseline calibrations being performed in response to a set dose change, the baseline calibrations including exposing the nitric oxide sensor to a zero concentration of nitric oxide;

supplying, via the nitric oxide delivery system, nitric oxide into an inspiratory flow of a patient breathing circuit, according to a set dosage;

monitoring output values from the nitric oxide sensor, the nitric oxide sensor in fluid communication with the breathing circuit, the output values indicative of the therapeutic gas concentration in the inspiratory flow;

determining the actual output value of the nitric oxide sensor during a baseline calibration of the nitric oxide sensor in accordance with the calibration schedule; and

augmenting the expected values correlated to nitric oxide concentrations to include the difference in the actual output value and the expected output value.

2. The method of claim 1 wherein the calibration schedule includes a set of values representing intended intervals between calibrations.

3. The method of claim 1 further comprising the step of postponing the baseline calibration when there is an alarm condition.

4. The method of claim 1 further comprising the step of postponing the baseline calibration when an alarm condition occurs within a predetermined interval before the time the baseline calibration is scheduled to occur.

5. The method of claim 1 further comprising the step of postponing the baseline calibration when the presence of an interfering gas is detected.

6. The method of claim 1 wherein the baseline calibration includes exposing the nitric oxide sensor to ambient air.

7. A method for compensating nitric oxide sensor drift affiliated with nitric oxide delivery, comprising:

storing a calibration schedule and a calibration line in a non-transitory computer-readable memory of a system controller, the calibration schedule providing zero concentration nitric oxide sensor calibrations in response to a change in set dose, and the calibration line providing output values from a nitric oxide sensor correlated to nitric oxide concentrations;

supplying, via a nitric oxide delivery system, nitric oxide to a patient breathing circuit according to a set dosage;

continuously monitoring output values from the nitric oxide sensor affiliated with the nitric oxide delivery system that are correlated to the concentration of nitric oxide in the breathing circuit;

identifying that a nitric oxide sensor calibration should be performed according to the calibration schedule;

exposing the nitric oxide sensor to a flow of a gas having a zero concentration of nitric oxide;

measuring the concentration of nitric oxide detected by the nitric oxide sensor during exposure to the gas having a zero concentration of nitric oxide; and

adjusting the calibration line according to a detected drift between a baseline and the concentration of nitric oxide measured when the nitric oxide sensor is exposed to the gas having a zero concentration of nitric oxide.

8. The method of claim 7 wherein the nitric oxide sensor is exposed to the gas having a zero concentration of nitric oxide for a predetermined interval before the calibration line is adjusted.

9. The method of claim 7 wherein the gas having a zero concentration of nitric oxide is ambient air.

10. The method of claim 7 further comprising the step of postponing the calibration when there is an alarm condition.

11. The method of claim 7 further comprising the step of postponing calibration when an alarm condition occurs within a predetermined interval before the scheduled calibration.

12. The method of claim 7 further comprising the step of postponing the calibration when the presence of an interfering gas is detected.

13. A method for calibrating for nitric oxide sensor drift in a nitric oxide delivery system, comprising:

storing a calibration schedule and a calibration line in a non-transitory computer-readable memory of a system controller;

wherein the calibration line has a baseline associated with a zero concentration of nitric oxide;

receiving via the system controller a set dosage of nitric oxide;

delivering nitric oxide to a breathing circuit according to the set dosage;

continuously collecting via a nitric oxide sensor measurements of the concentration of nitric oxide in the breathing circuit;

adjusting the measurements of the concentration of nitric oxide in the breathing circuit according to the calibration line and presenting a representation of the adjusted measurements on a display;

identifying that a calibration should be performed according to the calibration schedule;

performing a calibration, including:

exposing the nitric oxide sensor to a gas having a zero concentration of nitric oxide for a predetermined interval,

measuring the concentration of nitric oxide detected by the nitric oxide sensor while it is exposed to the gas having a zero concentration of nitric oxide, and

adjusting the calibration line according to the difference between the baseline and the measured concentration of nitric oxide measured when the nitric oxide sensor is exposed to the gas having a zero concentration of nitric oxide; and

resuming the continuous collecting of measurements of the concentration of nitric oxide in the breathing circuit.

14. The method of claim 13 wherein the baseline is associated with the nitric oxide concentration detected during a previous calibration.

15. The method of claim 13 wherein the gas having a zero concentration of nitric oxide is ambient air.

16. The method of claim 13 further comprising the step of postponing the calibration when there is an alarm condition.

17. The method of claim 13 further comprising the step of postponing the calibration when an alarm condition occurs within a predetermined interval before the scheduled calibration.

18. The method of claim 13 further comprising the step of postponing the calibration when the presence of an interfering gas is detected.

19. The method of claim 13 wherein the calibration schedule includes a set of values representing intended intervals between calibrations.

20. The method of claim 13 further comprising the step of postponing the calibration when there is an alarm condition.

Assignments (18)
SECURITY INTEREST Recorded Oct 28, 2025
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: GOLDMAN SACHS BANK USA, AS ADMINISTRATIVE AGENT
Reel/Frame 073375/0395 →
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
SECURITY INTEREST Recorded Aug 1, 2025
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 072331/0001 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 043601, FRAME 0025 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065610/0233 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Aug 18, 2017
From: MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 043601/0025 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 2, 2016
From: INO THERAPEUTICS LLC
To: THERAKOS, INC.
Reel/Frame 040201/0045 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 2, 2016
From: THERAKOS, INC.
To: MALLINCKRODT CRITICAL CARE FINANCE INC.
Reel/Frame 040201/0139 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 2, 2016
From: MALLINCKRODT CRITICAL CARE FINANCE INC.
To: MALLINCKRODT PHARMA IP TRADING DAC
Reel/Frame 040201/0276 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 2, 2016
From: MALLINCKRODT PHARMA IP TRADING DAC
To: MALLINCKRODT IP
Reel/Frame 040201/0505 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 2, 2016
From: MALLINCKRODT IP
To: MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
Reel/Frame 040201/0843 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 2, 2016
From: TOLMIE, CRAIG R.; MILSAP, JEFF; ACKER, JARON M.
To: INO THERAPEUTICS LLC
Reel/Frame 040200/0857 →